Ivan Gergel

Dr. Gergel is currently Senior Vice President, Drug Development & Chief Medical Officer of Nektar Therapeutics, where he oversees clinical strategy and activities, including direct supervision of clinical research, medical affairs, regulatory affairs and drug safety and surveillance. Dr. Gergel has more than 25 years of pharmaceutical leadership and drug development experience with deep expertise in all aspects of the clinical and regulatory process. Prior to Nektar, Dr. Gergel served as Executive Vice President, Research & Development of Endo Health Solutions, Inc. and Chief Scientific Officer, where he oversaw clinical, research, regulatory, project management and medical affairs. At Endo, Dr. Gergel was responsible for late-stage development programs and product approvals, including BEMA® Buprenorphine, Abuse-Deterrent Opana® ER for chronic pain, and Fortesta® and Aveed™ for hypogonadism. Prior, Dr. Gergel served as Senior Vice President of Scientific Affairs and President of the Forest Research Institute of Forest Laboratories, Inc., among other positions at the Forest Research Institute and Forest Laboratories, Inc., where he led successful development programs resulting in the approval of numerous NCEs for a range of CNS disorders and other medical conditions, including Celexa® for depression, Aerospan™ for asthma, Lexapro® for depression and generalized anxiety disorder and Namenda® for Alzheimer's disease. Dr. Gergel also oversaw the R&D team responsible for the successful in-licensing or acquisition of several new therapeutic agents. Prior, Dr. Gergel was a senior leader at SmithKline Beecham, where he led the U.S. clinical team responsible for the development and commercial support of Paxil®, which is approved to treat depression, panic disorder, generalized anxiety disorder and other conditions. Dr. Gergel received his M.D. from The Royal Free Medical School of The University of London and an MBA from the Wharton School of The University of Pennsylvania.